Date: Monday, October 22, 2018
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for determining adequate disease control. Lupus Low Disease Activity State (LLDAS) is a new clinical evaluation tool that assesses low disease activity state in lupus patients (Franklyn, et al. Ann Rheum Dis. 2016; 75: 1615-1621). Our study examines the relationship between the percentage of time patients spend in LLDAS and organ damage accrual, cardiovascular events, and death.
Methods: We studied a prospective longitudinal cohort of 246 patients with SLE during a 5-year follow-up period. Disease activity was measured using the SLE Disease Activity Index 2000 (SLEDAI-2K) and SELENA-SLEDAI physician global assessment (PGA). Cumulative organ damage was assessed at 1-year, 3-year, and 5-year intervals using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). The determination of LLDAS ≥ 50% of the time (LLDAS-50) was done retrospectively through clinical chart review. The following criteria for LLDAS included: (SLEDAI)-2K ≤4 without major organ activity, no new disease activity, PGA ≤1 (scale 0–3), ≤7.5 mg/day and stable dose of maintenance treatments. The longitudinal presence of carotid plaque and intima-media thickness (IMT) was measured at baseline and follow-up three years later. We determined the relationships between LLDAS, SDI, IMT, carotid plaque, and PREDICTS profile using multivariate regression analysis. T-tests were used for analysis of continuous variables and chi-squared for parametric variables.
Results: The average age was 42.8 years for patients in LLDAS-50 and 39.5 years for those not in LLDAS-50 (p = 0.048). Patients in LLDAS-50 or higher during the year after cohort entry had a mean SDI score of 1.5 (± 1.8) at 1 year, a mean SDI of 1.6 (± 1.9) at 3 years, and 1.9 (± 2.1) at 5 years after cohort entry. On average, patients who were in LLDAS-50 during the first year after cohort entry had lower SDI scores at 3 years and 5 years than patients who were not, reaching near significance (p = 0.06) for both.
There was no significant difference in measured IMT or plaque at baseline or at 3- or 5-year follow-up between patients in LLDAS-50 and those not in LLDAS-50 for the first year after baseline. However, patients in LLDAS-50 were significantly less likely to have major cardiac events (major stroke, myocardial infarction, positive stress test, angioplasty or percutaneous coronary intervention) or death compared with patients who were not in LLDAS-50, 20.7% and 38.2%%, respectively (p = 0.02).
Conclusion: We assessed SLE patients in LLDAS from our cohort of 246 patients. With regard to damage progression, there was near significantly less damage among those in LLDAS 50% of the time during the first year after cohort entry. Interestingly, although there were no differences between IMT, presence of carotid plaque, or plaque progression at any of the three time points, there was a statistically significant difference in number of cardiovascular events or death in the LLDAS-50 group. This supports LLDAS as a valid predictor of lower overall and cardiovascular damage in SLE patients.
To cite this abstract in AMA style:Tesfamicael R, Lam H, Lu O, Kapadia R, Siegel C, Sahakian L, Grossman JM, McMahon MA. Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/lupus-low-disease-activity-state-predicting-organ-damage-accrual-and-cardiovascular-risk-in-patients-with-systemic-lupus-erythematosus/. Accessed April 13, 2021.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-low-disease-activity-state-predicting-organ-damage-accrual-and-cardiovascular-risk-in-patients-with-systemic-lupus-erythematosus/